Drug
Fenebrutinib
Fenebrutinib: highest development phase Phase 2, developed by Roche. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Roche
Trials
| Drug | Phase | Indication |
|---|---|---|
| Fenebrutinib NCT07161258 | Phase 2 | Relapsing Multiple Sclerosis |
Latest
No recent events.
Follow Fenebrutinib on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.